TWI398249B - 神經治療用唑類化合物 - Google Patents

神經治療用唑類化合物 Download PDF

Info

Publication number
TWI398249B
TWI398249B TW095114655A TW95114655A TWI398249B TW I398249 B TWI398249 B TW I398249B TW 095114655 A TW095114655 A TW 095114655A TW 95114655 A TW95114655 A TW 95114655A TW I398249 B TWI398249 B TW I398249B
Authority
TW
Taiwan
Prior art keywords
group
phenyl
carbon atoms
tetrazol
compound
Prior art date
Application number
TW095114655A
Other languages
English (en)
Chinese (zh)
Other versions
TW200722085A (en
Inventor
崔龍文
金春吉
姜榮仙
李翰柱
李炫錫
具本澈
李恩豪
任大中
申惟珍
Original Assignee
愛思開生物製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37115369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI398249(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 愛思開生物製藥股份有限公司 filed Critical 愛思開生物製藥股份有限公司
Publication of TW200722085A publication Critical patent/TW200722085A/zh
Application granted granted Critical
Publication of TWI398249B publication Critical patent/TWI398249B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW095114655A 2005-04-22 2006-04-21 神經治療用唑類化合物 TWI398249B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67453005P 2005-04-22 2005-04-22

Publications (2)

Publication Number Publication Date
TW200722085A TW200722085A (en) 2007-06-16
TWI398249B true TWI398249B (zh) 2013-06-11

Family

ID=37115369

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095114655A TWI398249B (zh) 2005-04-22 2006-04-21 神經治療用唑類化合物

Country Status (22)

Country Link
US (1) US7598279B2 (enExample)
EP (1) EP1879873B1 (enExample)
JP (1) JP5035238B2 (enExample)
KR (1) KR101286499B1 (enExample)
CN (1) CN101228138B (enExample)
AR (1) AR053065A1 (enExample)
AU (1) AU2006237798B2 (enExample)
BE (1) BE2021C524I2 (enExample)
BR (1) BRPI0607529B8 (enExample)
CA (1) CA2606258C (enExample)
DK (1) DK1879873T3 (enExample)
ES (1) ES2441765T3 (enExample)
FI (1) FIC20210018I1 (enExample)
MX (1) MX2007013197A (enExample)
MY (1) MY148589A (enExample)
NL (1) NL301106I2 (enExample)
PL (1) PL1879873T3 (enExample)
PT (1) PT1879873E (enExample)
RU (1) RU2418792C2 (enExample)
TW (1) TWI398249B (enExample)
WO (1) WO2006112685A1 (enExample)
ZA (1) ZA200709994B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI826531B (zh) * 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物
TWI856977B (zh) * 2018-09-21 2024-10-01 南韓商愛思開生物製藥股份有限公司 胺基甲酸酯化合物及包括該化合物之組合於預防、緩解或治療急性壓力症或創傷後壓力症之用途

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
KR101468553B1 (ko) 2007-05-14 2014-12-09 에스케이바이오팜 주식회사 신규 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물,이를 함유하는 약제학적 조성물 및 상기 화합물 투여에의한 통증, 불안증 및 우울증 치료 방법
JP5444535B2 (ja) 2007-06-05 2014-03-19 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー 皮質カテコールアミン作動性神経伝達の調節物質としての新規な二置換フェニルピロリジン
CN102026988B (zh) * 2008-06-05 2013-07-03 爱思开生物制药株式会社 3-取代的丙胺化合物
ES2541590T3 (es) * 2009-06-22 2015-07-22 Sk Biopharmaceuticals Co., Ltd. Método para la preparación de éster (R)-1-aril-2-tetrazolil-etílico de ácido carbámico
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
CN102781436B (zh) 2009-11-06 2014-01-08 爱思开生物制药株式会社 纤维肌痛综合征的治疗方法
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
PT2800738T (pt) * 2012-01-06 2020-06-23 Novartis Ag Compostos heterocíclicos e métodos para a utilização dos mesmos
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
TWI655179B (zh) * 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
ITUA20161941A1 (it) * 2016-03-23 2017-09-23 Univ Degli Studi Di Siena Uso di derivati dell’acido 2-amminotiofen-3- carbossilico per il trattamento delle dipendenze da cibo
KR102421006B1 (ko) * 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도
KR102489052B1 (ko) * 2016-05-19 2023-01-16 에스케이바이오팜 주식회사 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
KR102421013B1 (ko) * 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
ES2901427T3 (es) * 2016-12-14 2022-03-22 Sk Biopharmaceuticals Co Ltd Preparación líquida parenteral que comprende un compuesto de carbamato
KR102635931B1 (ko) * 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 가려움증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
JP7090616B2 (ja) * 2016-12-14 2022-06-24 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物を含む口腔内崩壊錠
WO2018111006A1 (ko) * 2016-12-14 2018-06-21 에스케이바이오팜 주식회사 탈수초성 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
KR102635941B1 (ko) * 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
WO2018111008A1 (ko) * 2016-12-14 2018-06-21 에스케이바이오팜 주식회사 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
KR102739607B1 (ko) 2017-11-14 2024-12-06 에스케이바이오팜 주식회사 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물
ES2973111T3 (es) * 2017-11-14 2024-06-18 Sk Biopharmaceuticals Co Ltd Uso de un compuesto de carbamato para prevenir o tratar enfermedades asociadas con el aumento de la corriente tardía de sodio
MX2020004974A (es) * 2017-11-14 2020-08-24 Sk Biopharmaceuticals Co Ltd Uso del compuesto de carbamato para reducir o tratar trastornos del desarrollo que incluyen sindrome x fragil, sindrome de angelman o sindrome de rett.
ES2982316T3 (es) * 2017-11-14 2024-10-15 Sk Biopharmaceuticals Co Ltd Uso de un compuesto de carbamato para prevenir, aliviar o tratar las crisis de ausencia o la epilepsia que muestra crisis de ausencia
US11389429B2 (en) 2017-11-14 2022-07-19 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating or treating myotonia
ES3027977T3 (en) * 2017-11-14 2025-06-17 Sk Biopharmaceuticals Co Ltd Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease
KR20210047887A (ko) * 2018-09-21 2021-04-30 에스케이바이오팜 주식회사 중첩발작의 예방, 경감 또는 치료에 대한 카바메이트 화합물의 용도
CN112912076B (zh) * 2018-10-19 2024-07-16 爱思开生物制药株式会社 氨基甲酸酯化合物用于预防、缓解或治疗糖尿病性周围神经病变或化疗诱发性周围神经病变的用途
US10611737B1 (en) 2019-10-24 2020-04-07 Sk Biopharmaceuticals Co., Ltd. Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity
EP4062906A4 (en) * 2019-11-22 2024-01-03 SK Biopharmaceuticals Co., Ltd. ORAL PHARMACEUTICAL COMPOSITION COMPRISING A CARBAMAT COMPOUND AND PROCESS FOR PRODUCTION THEREOF
JP2023536341A (ja) * 2020-08-06 2023-08-24 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物を含む経口用固形製剤及びその製造方法
CN114317620B (zh) * 2020-09-29 2024-02-02 上海医药工业研究院 一种(r)-2-(2-氯苯基)环氧乙烷的生物制备方法
AR125970A1 (es) 2021-05-28 2023-08-30 Sk Biopharmaceuticals Co Ltd Formulaciones de suspensión acuosa para administración oral que comprenden un compuesto de carbamato
CN115974799B (zh) * 2021-10-14 2024-08-13 成都百裕制药股份有限公司 氨基甲酸酯取代的醇衍生物及其在医药上的应用
ES2931000B2 (es) * 2022-07-14 2023-07-07 Univ Madrid Complutense Proceso para la preparación de cenobamato
CN115716810A (zh) * 2022-11-15 2023-02-28 江苏艾立康医药科技有限公司 一种西诺氨酯的晶体形式及其制备方法
CN118239901A (zh) * 2023-03-15 2024-06-25 江苏恩华药业股份有限公司 一种氨基甲酸(r)-1-(2-氯苯基)-2-四唑-2-基乙酯的晶体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) * 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
US20040044033A1 (en) * 2002-08-26 2004-03-04 Yong-Moon Choi New benzoyl piperidine compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK181988A (da) * 1988-03-30 1989-10-01 Dumex Ltd As Thiocarbamidsyreester til brug som terapeutikum samt praeparat til behandling af alkoholmisbrug
RU2117664C1 (ru) * 1991-08-22 1998-08-20 Варнер-Ламберт Компани Производные тетразолсодержащего амида, смесь их изомеров, отдельные изомеры или фармацевтически приемлемые соли
RU2298552C2 (ru) * 2001-06-25 2007-05-10 СК Корпорейшн Карбаматы 2-гетероциклил-1,2-этандиолов
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) * 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
US20040044033A1 (en) * 2002-08-26 2004-03-04 Yong-Moon Choi New benzoyl piperidine compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI826531B (zh) * 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物
TWI856977B (zh) * 2018-09-21 2024-10-01 南韓商愛思開生物製藥股份有限公司 胺基甲酸酯化合物及包括該化合物之組合於預防、緩解或治療急性壓力症或創傷後壓力症之用途

Also Published As

Publication number Publication date
FIC20210018I1 (fi) 2021-06-14
EP1879873B1 (en) 2013-10-09
MY148589A (en) 2013-05-15
JP2008538557A (ja) 2008-10-30
EP1879873A1 (en) 2008-01-23
NL301106I2 (nl) 2021-08-03
CN101228138A (zh) 2008-07-23
JP5035238B2 (ja) 2012-09-26
BRPI0607529A2 (pt) 2009-09-15
ES2441765T3 (es) 2014-02-06
ZA200709994B (en) 2008-11-26
BRPI0607529B8 (pt) 2021-05-25
RU2418792C2 (ru) 2011-05-20
PT1879873E (pt) 2014-01-03
EP1879873A4 (en) 2011-06-15
US7598279B2 (en) 2009-10-06
BE2021C524I2 (enExample) 2025-12-10
NL301106I1 (nl) 2021-06-02
PL1879873T3 (pl) 2014-03-31
WO2006112685A1 (en) 2006-10-26
US20060258718A1 (en) 2006-11-16
AU2006237798A1 (en) 2006-10-26
BRPI0607529B1 (pt) 2021-05-18
KR101286499B1 (ko) 2013-07-16
CA2606258C (en) 2014-01-14
KR20080005437A (ko) 2008-01-11
AR053065A1 (es) 2007-04-18
CN101228138B (zh) 2012-11-21
DK1879873T3 (da) 2013-12-09
AU2006237798B2 (en) 2012-07-12
MX2007013197A (es) 2008-02-12
CA2606258A1 (en) 2006-10-26
RU2007143073A (ru) 2009-05-27
TW200722085A (en) 2007-06-16

Similar Documents

Publication Publication Date Title
TWI398249B (zh) 神經治療用唑類化合物
TWI282787B (en) 1-aryl-or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
CN101595098B (zh) 作为σ受体抑制剂的1,2,4-三唑衍生物
US8633175B2 (en) Compounds as antagonists or inverse agonists at opioid receptors
KR20080032188A (ko) 히스톤 탈아세틸화 효소 억제제
US20050119246A1 (en) 1H-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
CZ260295A3 (en) Indole derivatives as 5-ht1a and/or 5-ht2 ligands
JP2001502712A (ja) 束縛されたソマトスタチン・アゴニスト及びアンタゴニスト
WO2008068424A2 (fr) Derives de 2, 5-dihydro-3h-pyrazolo [4, 3-c] pyridazin-3-one substitues, leur preparation et leur utilisation comme ligands des recepteurs cb1 des cannabinoides
US8222254B2 (en) 1, 2, 4-triazole derivatives as serotonergic modulators
EA001217B1 (ru) СЕЛЕКТИВНЫЕ β-АДРЕНЕРГИЧЕСКИЕ АГОНИСТЫ
KR900002756B1 (ko) 오메가-[(헤테로)알킬]벤즈[cd]인돌-2-아민, 그들의 염 및 조성물과 그들의 제조방법
KR101603487B1 (ko) 3-치환된 프로판아민 화합물
FI76076C (fi) Foerfarande foer framstaellning av farmakologiskt vaerdefulla heterocykliska foereningar.
JP2001525398A (ja) 選択的β３アドレナリン作動性アゴニスト
CN110105286B (zh) 一种含有脲素骨架的取代杂环类化合物及其制备方法和用途
CA2757859A1 (fr) Derives de 1-alkyl-cinnolin-4(1h)-one substitues, leur preparation et leur application en therapeutique
TWI904134B (zh) 小分子干擾素基因刺激因子(sting)拮抗劑
US20160107991A1 (en) Processes and intermediates for preparing indole pharmaceuticals
CN103012295B (zh) 艾迪康唑的光学异构体及其制备方法与应用
FR2950055A1 (fr) Derives de 3-amino-cinnolin-4(1h)-one substitues, leur preparation et leur application en therapeutique